Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections

Gita Wasan Patel; Nimish Patel; Asma Lat; Kristen Trombley; Sam Enbawe; Kelli Manor; Raymond Smith; Thomas P Lodise Jr

doi:10.1016/j.diagmicrobio.2009.03.002

Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections

Diagn Microbiol Infect Dis. 2009 Jun;64(2):236-40. doi: 10.1016/j.diagmicrobio.2009.03.002.

Authors

Gita Wasan Patel¹, Nimish Patel, Asma Lat, Kristen Trombley, Sam Enbawe, Kelli Manor, Raymond Smith, Thomas P Lodise Jr

Affiliation

¹ Medical Center of Plano, TX 75075, USA.

PMID: 19500529
DOI: 10.1016/j.diagmicrobio.2009.03.002

Abstract

This comparison of intermittent versus extended-infusion piperacillin-tazobactam among patients with Gram-negative infections revealed similar mortality and length of stay. Outcomes remained similar when stratified by MIC value.

Publication types

Comparative Study

MeSH terms

Aged
Aged, 80 and over
Anti-Bacterial Agents / administration & dosage*
Anti-Bacterial Agents / therapeutic use
Female
Gram-Negative Bacterial Infections / drug therapy*
Gram-Negative Bacterial Infections / mortality
Humans
Infusions, Intravenous / methods
Length of Stay
Male
Microbial Sensitivity Tests
Middle Aged
Penicillanic Acid / administration & dosage
Penicillanic Acid / analogs & derivatives*
Penicillanic Acid / therapeutic use
Piperacillin / administration & dosage*
Piperacillin / therapeutic use
Tazobactam
Treatment Outcome

Substances

Anti-Bacterial Agents
Penicillanic Acid
Tazobactam
Piperacillin